Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2025-03-04 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a decision on a paid-in capital increase (유상증자결정). It details the amendment history of the capital increase, including changes to the issuance price and funding purpose. This type of filing is a formal regulatory announcement concerning changes to the company's capital structure and share issuance, which falls under the 'Share Issue/Capital Change' category.
2025-03-04 Korean
유상증자최종발행가액확정
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement regarding the final issuance price for a capital increase (paid-in capital increase/rights offering) by the company Addbiotech. It details the number of shares, the final price per share, and the calculation methodology. This falls under the category of capital structure changes and financing activities, specifically related to share issuance.
2025-03-04 Korean
[기재정정]증권신고서(지분증권) (2025.02)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by Addbiotech. It details specific amendments to the company's business description, risk factors, and financial projections (revenue estimates for 2025-2026). In the context of Korean financial filings (DART), a Securities Registration Statement is a formal regulatory filing required for public offerings or capital changes. Since it does not fit into the specific categories like '10-K' (Annual Report) or 'ER' (Earnings Release), and is a formal regulatory document, it is classified as a Regulatory Filing.
2025-02-27 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Addbiotech) announcing a significant change in financial results (revenue or profit/loss structure) as required by the Korea Exchange. This type of disclosure is a standard 'Earnings Release' (ER) in the Korean market, providing preliminary financial highlights before the final audited annual report is published. FY 2024
2025-02-14 Korean
[기재정정]증권신고서(지분증권) (2025.02)
Capital/Financing Update Classification · 98% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Korean Financial Supervisory Service (DART). It explicitly states it is a 'Correction Report' (정정신고) for a previous filing regarding a capital increase (유상증자). This document details changes to the offering schedule, subscription dates, and related procedural information for a public offering of shares. In the context of financial filings, a Securities Registration Statement is a regulatory filing that provides comprehensive details about a capital raise, which falls under the 'Regulatory Filings' (RNS) category as it is a formal, ongoing regulatory disclosure document.
2025-02-14 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details a correction (정정신고) to the previously filed capital increase plan, specifically updating dates for subscription, payment, and listing. This falls under the category of announcements regarding new share issues or capital changes.
2025-02-14 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.